Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Staloral 300 acari is a standardized aqueous sublingual immunotherapy (SLIT) solution developed by Stallergenes Greer. It contains a 1:1 mixture of allergen extracts from the house dust mites *Dermatophagoides pteronyssinus* and *Dermatophagoides farinae*, standardized to a concentration of 300 Index of Reactivity (IR). The therapy is indicated for the treatment of house dust mite-induced allergic rhinitis and allergic asthma (including extrinsic/allergic asthma). It works by modulating the immune system to induce allergen-specific tolerance, specifically by reducing the production of allergen-specific IgE and shifting the immune response away from a Th2-mediated allergic profile toward a regulatory T-cell response. It is administered sublingually via a minipump-predosed actuator, allowing for convenient at-home administration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on house dust mite allergen extract (Stallergenes Greer).